R
Ruth Harvey
Researcher at Francis Crick Institute
Publications - 45
Citations - 2514
Ruth Harvey is an academic researcher from Francis Crick Institute. The author has contributed to research in topics: Medicine & Antibody. The author has an hindex of 12, co-authored 28 publications receiving 1089 citations. Previous affiliations of Ruth Harvey include National Institute for Biological Standards and Control & University of Oxford.
Papers
More filters
Journal ArticleDOI
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Kevin W. Ng,Nikhil Faulkner,Georgina H. Cornish,Annachiara Rosa,Ruth Harvey,Saira Hussain,Rachel Ulferts,Christopher Earl,A.G. Wrobel,D.J. Benton,Chloe Roustan,William Bolland,Rachael Thompson,Ana Agua-Doce,Philip Hobson,Judith Heaney,Hannah Rickman,Stavroula Paraskevopoulou,Catherine F Houlihan,Kirsty Thomson,Emilie Sanchez,Gee Yen Shin,Moira J. Spyer,Dhira Joshi,Nicola O’Reilly,Philip A. Walker,Svend Kjaer,Andrew Riddell,Catherine Moore,Bethany R. Jebson,Meredyth G. Ll Wilkinson,Lucy R. Marshall,Elizabeth C. Rosser,Anna Radziszewska,Hannah Peckham,Coziana Ciurtin,Lucy R. Wedderburn,Rupert Beale,Charles Swanton,Sonia Gandhi,Brigitta Stockinger,John W. McCauley,Steve Gamblin,Laura E. McCoy,Peter Cherepanov,Eleni Nastouli,George Kassiotis,George Kassiotis +47 more
TL;DR: Using diverse assays for antibodies recognizing SARS-CoV-2 proteins, preexisting humoral immunity was detected and antibodies targeting the S2 subunit were particularly prevalent in children and adolescents.
Journal ArticleDOI
Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination.
Emma C Wall,Emma C Wall,Emma C Wall,Mary Wu,Ruth Harvey,Gavin Kelly,Scott Warchal,Chelsea Sawyer,Rodney S. Daniels,Philip Hobson,Emine Hatipoglu,Yenting Ngai,Saira Hussain,Jerome Nicod,Robert J. Goldstone,Karen Ambrose,Steve Hindmarsh,Rupert Beale,Rupert Beale,Rupert Beale,Andrew Riddell,Steve Gamblin,Michael Howell,George Kassiotis,George Kassiotis,Vincenzo Libri,Vincenzo Libri,Vincenzo Libri,Bryan Williams,Bryan Williams,Bryan Williams,Charles Swanton,Sonia Gandhi,Sonia Gandhi,David L.V. Bauer +34 more
Journal ArticleDOI
A conserved basic loop in hepatitis C virus p7 protein is required for amantadine-sensitive ion channel activity in mammalian cells but is dispensable for localization to mitochondria.
TL;DR: Demonstration of p7 ion channel activity in cellular membranes and its inhibition by amantadine affirm the protein as a target for future anti-viral chemotherapy.
Journal ArticleDOI
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses.
Tiong Kit Tan,Pramila Rijal,Pramila Rijal,Rolle Rahikainen,Anthony H. Keeble,Lisa Schimanski,Lisa Schimanski,Saira Hussain,Ruth Harvey,Hayes Jwp.,Jane C. Edwards,Rebecca K. McLean,Veronica Martini,M. Pedrera,Nazia Thakur,Carina Conceicao,Isabelle Dietrich,Holly Shelton,Anna B. Ludi,Ginette Wilsden,Clare Browning,Adrian K. Zagrajek,Dagmara Bialy,Sushant Bhat,Phoebe Stevenson-Leggett,Philippa Hollinghurst,Philippa Hollinghurst,Matthew Tully,Katy Moffat,Christopher Chiu,Ryan Waters,Ashley R. Gray,Mehreen Azhar,Valerie Mioulet,Joseph Newman,Amin S. Asfor,Alison Burman,Sylvia Crossley,John A. Hammond,Elma Tchilian,Bryan Charleston,Dalan Bailey,Tobias J. Tuthill,Simon P. Graham,Duyvesteyn Hme.,Tomas Malinauskas,Jiandong Huo,Jiandong Huo,Julia A. Tree,Karen R. Buttigieg,Raymond J. Owens,Raymond J. Owens,Miles W. Carroll,Miles W. Carroll,Rod S. Daniels,John W. McCauley,David I. Stuart,Huang K-Ya.,Huang K-Ya.,Mark Howarth,Alain Townsend,Alain Townsend +61 more
TL;DR: In this paper, a protein nanoparticle vaccine against SARS-CoV-2 was proposed based on the display of coronavirus spike glycoprotein receptor-binding domain (RBD) on a synthetic virus-like particle (VLP) platform, using SpyTag/SpyCatcher technology.
Posted ContentDOI
A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses
Tiong Kit Tan,Pramila Rijal,Pramila Rijal,Rolle Rahikainen,Anthony H. Keeble,Lisa Schimanski,Lisa Schimanski,Saira Hussain,Ruth Harvey,Jack W.P. Hayes,Jane C. Edwards,Rebecca K. McLean,Veronica Martini,M. Pedrera,Nazia Thakur,Carina Conceicao,Isabelle Dietrich,Holly Shelton,Anna B. Ludi,Ginette Wilsden,Clare Browning,Adrian K. Zagrajek,Dagmara Bialy,Sushant Bhat,Phoebe Stevenson-Leggett,Philippa Hollinghurst,Philippa Hollinghurst,Matthew Tully,Katy Moffat,Christopher Chiu,Ryan Waters,Ashley R. Gray,Mehreen Azhar,Valerie Mioulet,Joseph Newman,Amin S. Asfor,Alison Burman,Sylvia Crossley,John A. Hammond,Elma Tchilian,Bryan Charleston,Dalan Bailey,Tobias J. Tuthill,Simon P. Graham,Tomas Malinauskas,Jiandong Huo,Jiandong Huo,Julia A. Tree,Karen R. Buttigieg,Raymond J. Owens,Raymond J. Owens,Miles W. Caroll,Miles W. Caroll,Rodney S. Daniels,John W. McCauley,Kuan-Ying A. Huang,Kuan-Ying A. Huang,Mark Howarth,Alain Townsend,Alain Townsend +59 more
TL;DR: The induction of potent and polyclonal antibody responses by RBD-SpyVLP provides strong potential to address clinical and logistic challenges of the COVID-19 pandemic.